Melanoma, which most often results from genome instability and malignant growth of melanocytes, is a worldwide epidemic. As reported by the World Health Organization, 160 000 new cases of melanoma, and 48 000 melanoma-related deaths occurred worldwide in 2006. [1] Genome instability in melanocytes, leading to melanoma, is most often caused by chronic exposure to UVA and UVB radiation, which results in the generation of highly reactive free radicals, as well as photoinduced dimerization of thymine nucleotides in genomic DNA. As a mechanism of combating these deleterious effects of UV radiation on the cell, a large number of organisms, including humans, produce melanin, a complex photoprotectant polymer capable of absorbing 99.9 % of UV radiation.
[2] While produced in a number of areas including the brain, eyes, adrenal gland, and hair, production of melanin in melanocytes results in the pigmentation of skin. The production of melanin (melanogenesis) is a complex cellular process, involving over 100 genes, which regulate melanin biosynthesis, intracellular trafficking of melanogenic enzymes to melanosomes, and intercellular trafficking to keratinocytes.
[3] Although numerous reports have shed light on key steps in melanin biosynthesis, regulation and trafficking, our current understanding of melanogenesis remains A C H T U N G T R E N N U N G incomplete.
Small molecules that upregulate melanin biosynthesis in melanocytes hold the potential to reduce UV-radiation-induced skin damage and the onset of melanoma. Additionally, such reagents may find use in the treatment of hypopigmentation disorders such as albinism. Conversely, a significant number of skin diseases such as melasma, postinflamitory melanoderma and solar lentigines are the result of increased melanin biosynthesis.
[4] Small molecules that increase or decrease melanin biosynthesis in melanocytes can be used as tools to examine the cellular mechanisms underlying melanogenesis, and potentially reveal previously unknown therapeutic targets in melanin-A C H T U N G T R E N N U N G related diseases.
Currently, only a small number of molecules are known to alter the cellular level of melanin in melanocytes. The naturally occurring molecule forskolin, [5] and synthetic compounds such as isobutylmethylxanthine [6] (IBMX) are known to regulate adenylyl cyclase and phosphodiesterases, respectively, resulting in an increase in melanin biosynthesis in melanocytes. When applied topically to mice, forskolin provides protection against UV-induced carcinogenesis of skin. [7] Recently, a synthetic reagent dubbed "melanogenin" was identified from small-molecule screening, which increases melanin production in melanocytes. [8] Unlike forskolin and IBMX, which act on known members of the canonical melanogenesis pathway, melanogenin was found to bind prohibitin and mitochondrial F 1 F 0 -ATPase resulting in retrafficking of tyrosinase and tyrosinase-related protein 1. This example, [8] and others, [9] highlight the utility of small molecules with unique biological function to examine complex cellular processes, such as melanogenesis, and identify potential therapeutics and novel therapeutic targets.
As part of a research program designed to identify additional synthetic molecules capable of altering the cellular level of melanin in melanocytes, we synthesized and screened a 75-member targeted combinatorial library of functionally diverse amides. Library members were synthesized from carboxylic acid (A-E) and amine (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) building blocks in a two-step process to generate functionally diverse amides from inexpensive starting materials (Scheme 1).
An immortalized murine melanocyte cell line (melan-a) was used to screen the library for compounds that alter melanin levels in melanocytes (see Experimental Section for details). Forskolin was used as a positive control, while cells treated with growth media containing 0.1 % DMSO (vehicle control) were used as a negative control. After 72 h incubation, cells were counted by hemocytometry and the results were used to measure the cytotoxicity of each library member, as well as to normalize the cellular level of melanin per cell in different samples. The melanin levels in these same samples were then measured by comparing the absorbance of the sample at 490 nm (A 490 ) to a standard curve using purified melanin and normalized to cell count.
From this screen, four compounds were identified that increase the cellular level of melanin by greater than 1.5-fold in comparison to the vehicle control. The most active compounds identified in our screen share structural features. 2-Ethylquinoline and furan moieties are represented in the carboxylic acid building block, and three of the four compounds have either ortho-or para-fluorinated aryl groups in the amine building block. Of these four compounds, derivative A7 is the most effective activator of melanogenesis. Treating melan-a melanocytes with 2.5 mm A7 resulted in a 1.8 AE 0.3-fold increase in the cellular level of melanin, in comparison to treatment with vehicle control (Figure 1) .
Treatment of melan-a cells with 0.5, 1.0, 2.5, or 5.0 mm A7 resulted in a dose-dependent increase in the cellular level of melanin, with a maximum effect observed at a dose ! 2.5 mm. In contrast, compound A7 did not have a significant effect on melan-a proliferation under the concentrations tested (Figure 2 ). In addition to these data, an A7-dependent increase in the cellular level of melanin was confirmed by microscopy. Unlike cells treated with vehicle control, which lacked dark features, cells treated with A7 had significant pigmentation. Closer analysis of A7-treated cells revealed a large number of dark punctate foci within each cell, consistent with high levels of melanin present in melanosomes (Figure 3) . [10] Taken together, these data are consistent with a model in which the cellular level of melanin is significantly increased by treatment with compound A7.
In addition to an increase in cell pigmentation, we observed significant changes in the morphology of melan-a cells following treatment with A7 (Figure 3 ). This observation further supports an A7-dependent increase in melanogenesis. Previous reports have shown a strong correlation between changes in melanocyte morphology, such as dendricity, and the cellular level of melanin. [11] In order to measure the observed change in morphology, as well as obtain additional data on the response of melanocytes to compound A7, we measured the dendricity of melan-a cells 72 h after treatment with vehicle control or A7 (see Experimental Section for details). On average, 36 % AE 3.1 % of cells treated with growth media containing vehicle control had greater than two dendrites per cell. In comparison, 69 % AE 5.2 % of cells treated with A7 had greater than two dendrites per cell (Figure 4 ). These data confirm our initial observations, and support A7-dependent induction of melanogenesis in melan-a cells.
We next sought to identify cellular targets of A7. Tyrosinase is a well-characterized enzyme that catalyzes the oxidation of phenols (such as tyrosine) and is known to play a critical role in the canonical melanin biosynthetic pathway. [12] In this pathway, tyrosinase catalyzes the hydroxylation of tyrosine to generate l-DOPA. An increase in the activity or expression of tyrosinase therefore results in an increase of melanin in melanocytes. [13] The direct correlation between the catalytic activity of tyrosinase or tyrosinase overexpression, and melanin production, makes tyrosinase a good starting point to examine potential cellular targets of compound A7 that result in an increased cellular level of melanin. In addition, because the role of tyrosinase in the canonical melanogenesis pathway is well established, the effect compound A7 has on tyrosinase activity and expression provides a valuable starting point for future efforts to further elucidate the mechanism of action of compound A7.
Tyrosinase activity was measured using a previously reported technique. [14] The cellular level of tritiated water, which is formed as a byproduct of tyrosinase-catalyzed hydroxylation of On average, cells treated with vehicle control had 73 422 AE 781 scintillation counts per minute (cpm). In comparison, cells treated with A7 or forskolin had 99 567 AE 10 390 cpm and 121 588 AE 5 016 cpm, respectively (Figure 5 a) . On average, this correlates to a 35 % increase in tyrosinase activity in cells treated with compound A7 and a 65 % increase in tyrosinase activity in cells treated with forskolin. These data suggest that treating melan-a cells with compound A7 results in a statistically significant increase in the activity of tyrosinase, a known participant in the canonical melanin biosynthetic pathway.
At least two models explain an A7-dependent increase in tyrosinase activity. In one model, treatment with compound A7 has no effect on the cellular level of tyrosinase, but does result in increased catalytic activity of tyrosinase. For example, a direct or allosteric interaction between compound A7 and tyrosinase, as well as an interaction between compound A7 and does not influence the catalytic activity of tyrosinase, but does result in the overexpression of tyrosinase. Overexpression of tyrosinase would result in an increase of tyrosinase-dependent oxidation of tyrosine, resulting in higher cellular levels of melanin.
In an effort to provide support for one of these models, the cellular level of tyrosinase was measured in melan-a melanocytes treated with growth media containing either vehicle control or A7. Tyrosinase levels were measured by Western blot and normalized to b-actin (see Experimental Section). Cells treated with vehicle control or A7 were found to have similar cellular levels of tyrosinase ( Figure 5 b and c) . These data are consistent with a model in which treatment with compound A7 in melanocytes has no effect on tyrosinase expression, but does increase the activity of tyrosinase through mechanisms that are currently unknown.
The production of melanin in melanocytes is a critical defense mechanism to combat genome instability and disease, as a result of chronic exposure to UV radiation.
[2] Small molecules that increase the cellular level of melanin in melanocytes therefore have significant therapeutic potential, and may be used to treat diseases such as albinism. In addition, a number of diseases are the result of hypermelanogenesis.
[4] Small molecules that upregulate melanin production can be used to study melanogenesis, and have the potential to reveal new therapeutic targets for melanin-related diseases.
In this communication, we described the synthesis of a targeted combinatorial library of functionally diverse amides, and the screening of this library for molecules that alter the cellular level of melanin in melanocytes. Four compounds were identified that resulted in a greater than 1.5-fold increase in melanin production in melan-a cells, in comparison to cells treated with vehicle control. Treating melan-a melanocytes with the most active molecule, A7, resulted in a 1.8 AE 0.3-fold increase in the cellular level of melanin, in comparison to cells treated with the vehicle control. An A7 dose-dependent increase in the cellular level of melanin was observed in melan-a cells treated with 0.5-5.0 mm of A7, further supporting the hypothesis of A7-dependent melanogenesis.
In addition to an increase in pigmentation, an increase in the dendricity of melanocytes has been shown to correlate well with melanogenesis. [11] On average, 69 % of melan-a cells treated with A7 had > 2 dendrites per cell, whereas only 36 % of melan-a cells treated with vehicle control had > 2 dendrites per cell. Tyrosinase-catalyzed oxidation of l-tyrosine to l-DOPA is a well studied and critical step in melanin biosynthesis; as a starting point to examine the mechanism of A7-dependent Taken together, our data show that compound A7 is a novel and potent activator of melanogenesis in melan-a melanocytes, and supports a model in which compound A7 acts by increasing the tyrosinase-dependent oxidation of tyrosine, resulting in higher cellular levels of melanin. A7 is prepared in a simple two-step synthesis, and has significant potential as a tool to study melanogenesis, as well as mechanisms by which tyrosinase activity can be increased in a small-molecule-dependent manner. Future studies examining the role A7 plays in melanogenesis and tyrosinase activity, as well as structureactivity relationships centered on A7, are currently underway and will be reported in due course.
Experimental Section Chemistry
Library synthesis: Carboxylic acid A was prepared using a previously reported method. [15] A solution of carboxylic acid A-E (1.0 equiv) in anhyd CH 2 Cl 2 was treated with oxalyl chloride (3.0 equiv) and catalytic DMF (0.01 equiv). Evolution of gas was observed following addition of DMF. The reaction vial (5 mL) was capped with a rubber septum and the reaction was stirred at 25 8C under a N 2 atmosphere for 18 h. The solvent was removed in vacuo and the resultant acid chloride was redissolved in anhyd CH 2 Cl 2 (7.0 mL). An aliquot of the acid chloride solution (0.5 mL) was placed in a glass vial (5 mL) and treated with Et 3 N (1.05 equiv), DMAP (0.05 eq), and amine 1-15 (1.05 eq). Vigorous evolution of gas was observed upon addition of amine. The reaction vial was capped with a rubber septum and stirred at 25 8C under a N 2 atmosphere for 36 h. The crude reaction mixture was passed through a plug of silica gel, eluted with hexanes/EtOAc (1:1), and dried under a stream of N 2 . Any remaining solvent was removed by freeze drying. The purity of each compound was determined by HPLC on a Shimadzu LC-2010A chromatograph using a Shim-pack CLC-ODS-(M) C 18 column with a detector setting of 254 nm. Structures were confirmed by ESI-MS. The most effective compound identified in our screen, A7, was further characterized by 1 H NMR, 13 C NMR, IR, and HRMS (see Supporting Information). All compounds were determined to be ! 90 % pure and stored as 25 mm solutions in DMSO. 
Biology
Cell culture: Melan-a cells [16] were obtained from the Wellcome Trust Functional Genomics Cell Bank, and were cultured in RPMI 1640 medium (Sigma-Aldrich) with 10 % FBS, 0.2 mm TPA, 2 mm glutamine, 5 I.U. penicillin, and 5 mg mL À1 streptamycin. All cells were cultured at 37 8C with 5 % CO 2 .
Initial library screening: Melan-a cells (1 10 5 ) were plated in a 24-well tissue culture plate and allowed to stably adhere in 1 mL of RPMI 1640/10 % FBS/0.2 mm TPA (referred to herein as growth media) for 18 h at 37 8C under 5 % CO 2 . Media was then removed and replaced with growth media containing either 2.5 mm forskolin, which serves as a positive control for increased melanin levels, or 2.5 mm library member. As a negative control, cells were treated with growth media containing 0.1 % DMSO (referred to herein as vehicle control). After 72 h, cells were trypsinized from the tissue culture multiwell plate, individually placed in a 1.5 mL plastic tube, pelleted, resuspended, and washed twice with phosphate buffered saline (PBS, pH 7.2). Following resuspension in 1 mL of PBS, a small aliquot of each cell mixture was removed, and cells were counted by hemocytometry. Cell count was used to measure the cytotoxicity of each library member, as well as to normalize the cellular level of melanin per cell in different samples. After counting, the cell samples were repelleted, and lysed in 800 mL of 1m NaOH/PBS for 2 h on ice. Cell lysate was homogenized by pipetting, and melanin levels were measured by A 490 . The cellular level of melanin in each sample was determined by reference to an A 490 standard curve using purified melanin (Sigma-Aldrich) and normalized to cell count.
Microscopy:
To further confirm an A7-dependant increase in the cellular level of melanin, melan-a melanocytes were grown on matrigel-treated glass slides and treated with growth media containing either vehicle control or 2.5 mm A7 and incubated at 37 8C under 5 % CO 2 for 72 h. Cells were then washed three times with PBS and imaged.
Melanocyte morphology was also observed using microscopy. 1 10 4 melan-a cells were plated on a matrigel-coated glass slide and allowed to adhere for 18 h. Cells were then treated in triplicate with growth media containing either vehicle control or 2.5 mm A7 and cultured for 72 h at 37 8C under 5 % CO 2 . Cells were washed three times with PBS and fixed with 4 % formaldehyde/PBS. The cell nucleus was stained with hematoxylin, and cells were imaged by microscopy. The number of dendrites per cell were counted manually.
Tyrosinase activity: Tyrosinase activity was determined using a previously reported method.
[14] Briefly, 1 10 5 melan-a cells were plated in a 24-well tissue culture plate and allowed to stably adhere for 18 h. Cells were then treated in quadruplet with growth media containing either vehicle control or 2.5 mm A7 and cultured for 72 h. Melan-a cells were trypsinized from the tissue culture plate, pelleted, washed three times in PBS, and repelleted. Melan-a cell pellets were lysed in 75 mL of tyrosinase harvesting buffer (80 mm K 2 PO 4 , 1 % CHAPS, 0.5 mm PMSF, 5 mg mL À1 aprotinin, PICO2 protease inhibitor cocktail, pH 6.8) for 2 h on ice and spun at 13,000 rpm for 15 min at 4 8C to pellet cellular debris. Total protein in the soluble lysate was quantified via Bradford assay (BioRad). In quadruplicate, 5 mg of total protein was transferred to a 2.0 mL tube containing 250 mL of 80 mm K 2 PO 4 (pH 6.8). To one of the tubes serving as the boiled control, 2 mL of 2-mercaptoethanol was added and this sample was boiled for 30 min. To each tube, 20 mL of tyrosinase assay solution (3.375 mm l-tyrosine, 337.5 mm 3,4-dihydroxy-l-phenylalanine, 0.7 mCi [ 3 H]tyrosine (Perkin-Elmer, Boston, USA, 5 mL of stock from supplier), 40 mm K 2 PO 4 , pH 6.8) was added and incubated at 37 8C for 1 h. Then, 375 mL of 0.2 % BSA, followed by 375 mL trichloroacetic acid was added to each tube. After addition of trichloroacetic acid, protein precipitated and the samples were spun at 13 000 rpm for 10 min. 750 mL of the cleared supernatent was transferred to a 2.0 mL tube containing 500 mL of a prewashed 33 % charcoal slurry in 40 mm K 2 PO 4 (pH 6.8) and agitated for 1 h at 23 8C. Charcoal was then pelleted by spinning at 13,000 rpm for 15 min. Aliquots (1.0 mL) of the resulting supernatant was transferred to scintillation vials filled with 5 mL of scintillation fluid, and [ 3 H] levels were counted. Supernatant from melan-a cells incubated in growth media containing either 2.5 mm forskolin or vehicle control was used as a positive and negative control, respectively. Supernatant from melan-a cells that were untreated and boiled after lysis to denature total cellular protein was used to determine background count level. Background was subtracted from the value obtained for each sample to provide an absolute measurement of tyrosinase activity.
Western blot: Melan-a melanocytes (1 10 5 cells) were plated in a 12-well tissue culture plate and allowed to stably adhere for 18 h at 37 8C under 5 % CO 2 . Cells were then treated with growth media containing either vehicle control or 2.5 mm A7, and cultured for 72 h. Growth media was then removed and cells were washed three times with 4 8C PBS. Cells were lysed with 200 mL RIPA buffer (Boston Bioproducts) containing a protease inhibitor cocktail (CalBioChem) for 15 min. The resulting cell lysate was resolved by SDS-PAGE on a 10 % acrylamide gel (Invitrogen). The proteins on the gel were transferred by electroblotting onto a nitrocellulose membrane (BioRad) and membranes were blocked in 5 % milk for 1 h. Membranes were then incubated in primary antibody against tyrosinase protein (Zymed Co., San Francisco, USA, T311; mouse monoclonal) and b-actin (Abcam, Boston, USA; mouse polyclonal) in 5 % milk overnight at 4 8C. The membrane was washed three times with PBS and treated with secondary antibody (HRP goat antimouse IgG, Sigma Co.) in blocking buffer (Li-COR Biosciences) for 30 min. The membrane was washed three times with 50 mm Tris containing 150 mm NaCl and 0.05 % Tween-20 (pH 7.4). Visualization of immunoreactive proteins was accomplished with an enhanced chemiluminescence reaction (Pierce Chemical, Rockford, USA). Densitometry was performed using Image J.
